Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.37 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.37 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 5/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29435935 | 1.00 | HSD17B1 (0.40) | HSD17B1CYP1A2AURKACYP1A1CDC25B | |
| SCHEMBL23027524 | 0.89 | BRD4 (0.40) | HSD17B1CYP1A2AURKACYP1A1CDC25B | |
| SCHEMBL18353017 | 0.83 | TXNRD1 (0.42) | CYP1A2AURKACYP1A1CDC25BTXNRD1 | |
| SCHEMBL783668 | 0.83 | KDM4E (0.41) | HSD17B1KDM4EHPGDALDH1A1GLA | |
| SCHEMBL29605666 | 0.83 | KDM4E (0.41) | HSD17B1KDM4EHPGDALDH1A1GLA | |
| SCHEMBL29690461 | 0.83 | TXNRD1 (0.42) | CYP1A2AURKACYP1A1CDC25BTXNRD1 | |
| SCHEMBL13568681 | 0.78 | TXNRD1 (0.50) | HSD17B1CYP1A2AURKACYP1A1CDC25B | |
| SCHEMBL29604667 | 0.76 | KDM4E (0.47) | KDM4EHPGDALDH1A1GLAGAA | |
| SCHEMBL14430310 | 0.76 | KDM4E (0.47) | KDM4EHPGDALDH1A1GLAGAA | |
| SCHEMBL14430376 | 0.76 | PTGS1 (0.37) | KDM4EHPGDALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4660185-A1 | NAV1.7- AND/OR NAV1.8-INHIBITING AMIDES, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | Eurofarma Laboratórios S.A. (BR) | 2025-12-10 | — | — | EP | disclosed |
| EP-3919056-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024159288-A1 | NAV1.7- AND/OR NAV1.8-INHIBITING AMIDES, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2024-08-08 | — | — | WO | disclosed |
| US-RE49948-E1 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| EP-3586835-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ARYL ETHERS | PELOTON THERAPEUTICS INC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2023165523-A1 | AROMATIC RING-SUBSTITUTED METHOXY DERIVATIVE AND USE THEREOF | 上海璎黎药业有限公司 | 2023-09-07 | — | — | WO | disclosed |
| CN-116693514-A | Aromatic ring substituted methoxy derivative and application thereof | 上海璎黎药业有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-1651637-A1 | 3-AMINO CHROMAN AND 2-AMINO TETRALIN DERIVATIVES | Wyeth (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | WYETH (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2005012291-A1 | 3-AMINO CHOMAN AND 2-AMINO TETRALIN DERIVATIVES | WYETH (US) | 2005-02-10 | — | — | WO | disclosed |
| EP-0684237-B1 | MORPHOLINE DERIVATIVE | YAMANOUCHI PHARMA CO LTD (JP) | 1999-12-08 | — | — | EP | disclosed |
| US-5521180-A | Morpholine derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1996-05-28 | — | — | US | disclosed |
| EP-0684237-A1 | MORPHOLINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1995-11-29 | — | — | EP | disclosed |
| EP-0425946-B1 | Iso- and heterocyclic phenylsulphonamides | BAYER AG (DE) | 1994-08-17 | — | — | EP | disclosed |
| US-5264458-A | Antithrombotic iso- and heterocyclic phenylsulphonamides | BAYER AKTIENGESELLSCHAFT (DE) | 1993-11-23 | — | — | US | disclosed |
| US-5191092-A | ANTITHROMBOTIC ISO- AND HETEROCYCLIC PHENYLSULPHONAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1993-03-02 | — | — | US | disclosed |
| EP-0425946-A2 | Iso- and heterocyclic phenylsulphonamides | BAYER AG (DE) | 1991-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | HSD17B1 1639/4885CYP1A2 760/4885AURKA 4764/4885 |
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | TPH2, HTR2C, HTR7 | HSD17B1 3398/4885CYP1A2 1468/4885AURKA 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.